Earlier this year, Mission Bio completed their first technology transfer of a cell and gene therapy assay to Avance Biosciences. The goal was to translate Mission Bio's work to a good manufacturing practice (GMP) environment, supporting the firms' shared partners in clinical trials.

"As a company, we're very proud of what we can do as part of the ecosystem to support our partners in their success," Zhang said.

"The platform is very uniquely suited for a better understanding of the heterogeneity behind drug resistance for cancer. And now we're playing a super important role in supporting cell and gene therapy."

Watch the video below to learn more.

Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectors
It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors,...

Advances in gene therapy call for education, patient advocate says
Durhane Wong-Rieger, board chair of Rare Diseases International, spoke to ScienceBoard.net at the Cell & Gene Meeting on the Med last week in...

Investment continues in cell and gene sector, despite disruptions
Investment in the cell and gene therapy sector remains robust, despite the disruptions over the last several years due to the COVID-19 pandemic. That's...

Regional government steps in to boost gene therapy manufacturing in Spain
BARCELONA, SPAIN -- Early cooperation between the government of the Basque region in northern Spain and companies can help boost manufacturing of gene...

Mission Bio transfers 1st Tapestri GMP-ready CGT assay
Mission Bio has completed the first tech transfer of a clinical trial-, good manufacturing practices (GMP)-ready cell and gene therapy (CGT) assay from...